Nu Skin Enterprises Inc. (NUS) exhibits 69.4% gross margins and 6.7% return on invested capital within Health Care (Other Pharmaceuticals), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 69.4% gross profitability converts into 4.4% operating margin and 6.7% ROIC, outpacing sector cost of capital.
ROIC: 6.7% // GM: 69.4%YoY revenue trajectory of -14.3% paired with 20.15% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -14.3% // FCF YLD: 20.15%Altman Z-Score of 3.54 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.54 // F-SCORE: 7/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $4.65 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Other Pharmaceuticals require continuous execution to defend 10.8% net margins.
NET MARGIN: 10.8% // D/E: 0.25x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for NUS & activate live FRED threshold breach alerts.